*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
293T , A431 , H1299 , HeLa , HepG2 , Molt-4 , Raji
0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1mg/ml(Please refer to the vial label for the specific concentration.)
Recombinant protein encompassing a sequence within the C-terminus region of human VEGF Receptor 3. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
FLT41 antibody, LMPH1A antibody, PCL antibody, VEGFR3 antibody, FLT4 antibody, fms-like tyrosine kinase 4 antibody, VEGFR-3 antibody, FLT-4 antibody, soluble VEGFR3 variant 1 antibody, vascular endothelial growth factor receptor 3 antibody, tyrosine-protein kinase receptor FLT4 antibody, soluble VEGFR3 variant 2 antibody, soluble VEGFR3 variant 3 antibody, fms-related tyrosine kinase 4 antibody
Membrane; Single-pass type I membrane protein
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq]